Capital Fund Management (CFM)
AUPH icon

Capital Fund Management (CFM)’s Aurinia Pharmaceuticals AUPH Stock Holding History

Capital Fund Management (CFM)’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,458
Closed -$202K – 1977
2024
Q4 		$202K Sell
22,458
-5,111
-19% -$41.7K ﹤0.01% 1994
2024
Q3 		$202K Sell
27,569
-42,190
-60% -$262K ﹤0.01% 1937
2024
Q2 		$398K Sell
69,759
-9,075
-12% -$47.8K ﹤0.01% 1795
2024
Q1 		$395K Buy
78,834
+1,200
+2% +$8.14K ﹤0.01% 1899
2023
Q4 		$698K Sell
77,634
-82,884
-52% -$683K ﹤0.01% 1922
2023
Q3 		$1.25M Buy
160,518
+99,678
+164% +$975K ﹤0.01% 1562
2023
Q2 		$589K Buy
60,840
+36,331
+148% +$377K ﹤0.01% 1544
2023
Q1 		$269K Buy
+24,509
New +$216K ﹤0.01% 1512
2022
Q4 		– Sell
-190,104
Closed -$1.43M – 1392
2022
Q3 		$1.43M Buy
190,104
+48,360
+34% +$419K 0.01% 963
2022
Q2 		$1.42M Sell
141,744
-606
-0.4% -$6.77K 0.01% 949
2022
Q1 		$1.76M Buy
+142,350
New +$2.2M 0.01% 1004

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capital Fund Management (CFM)'s AUPH Position: Q1 2025 in Review

Capital Fund Management (CFM) sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2025, closing a stake of 22,458 shares — an estimated $202K sold.

Capital Fund Management (CFM) first reported a position in AUPH in Q1 2022 and held it in 11 quarters. The position peaked at $1.76M in Q1 2022. 214 funds tracked by Wall St. Rank hold AUPH as of Q1 2025.

  • Capital Fund Management (CFM) reported no remaining Aurinia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 22,458 Aurinia Pharmaceuticals shares in Q1 2025, an estimated $202K.
  • Capital Fund Management (CFM) first reported a position in Aurinia Pharmaceuticals in Q1 2022 and held it in 11 quarters.
  • Capital Fund Management (CFM)'s Aurinia Pharmaceuticals position peaked at $1.76M in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2025, filed 14 May 2025.